Conclusion
METASTATIC BREAST CANCER, BONE METASTASES
Saracatinib did not improve outcomes in post-menopausal women with metastatic breast cancer. There was no observed beneficial effect on bone metastases.CRUKE/11/023, ISRCTN23804370.